Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM9JON3)

Drug Name
SU5402 Drug Info
Synonyms
su5402; 215543-92-3; SU 5402; SU-5402; 3-[3-(2-Carboxyethyl)-4-methylpyrrol-2-methylidenyl]-2-indolinone; (Z)-3-(4-methyl-2-((2-oxoindolin-3-ylidene)methyl)-1H-pyrrol-3-yl)propanoic acid; CHEMBL89363; 3-[(3-(2-CARBOXYETHYL)-4-METHYLPYRROL-2-YL)METHYLENE]-2-INDOLINONE; J-502595; 3-{[3-(2-carboxyethyl)-4-methylpyrrol-2-yl]methylene}-2-indolinone; 3-[4-methyl-2-[(Z)-(2-oxo-1H-indol-3-ylidene)methyl]-1H-pyrrol-3-yl]propanoic acid; (Z)-3-(4-Methyl-2-((2-oxoindolin-3-ylidene)-methyl)-1H-pyrrol-3-yl)propanoic acid
Indication
Disease Entry ICD 11 Status REF
Multiple myeloma 2A83 Investigative [1]
Cross-matching ID
PubChem CID
5289418
ChEBI ID
CHEBI:63449
CAS Number
CAS 215543-92-3
TTD Drug ID
DM9JON3

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
DOT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Patented Agent(s)
Investigative Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Fibroblast growth factor receptor 3 (FGFR3)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Pemigatinib DM819JF Cholangiocarcinoma 2C12.10 Approved [6]
Trapidil DMY67U8 Acute coronary syndrome BA41 Phase 4 [1]
E-3810 DM42PFT Solid tumour/cancer 2A00-2F9Z Phase 3 [7]
TKI258 DMYLT67 Renal cell carcinoma 2C90 Phase 3 [8]
BMS-582664 DMDAN8H Hepatocellular carcinoma 2C12.02 Phase 3 [8]
Debio 1347 DMZW50O Solid tumour/cancer 2A00-2F9Z Phase 2 [9]
B-701 DMOMDA4 Bladder cancer 2C94 Phase 2 [10]
Recifercept DML8N3Y Achondroplasia LD24.00 Phase 2 [11]
MK-2461 DM21WBH Alzheimer disease 8A20 Phase 1/2 [12]
AEE-788 DMEOS5K Solid tumour/cancer 2A00-2F9Z Phase 1/2 [8]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Centrosomal protein 43 (CEP43)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [13]
Ciclosporin DMAZJFX Graft-versus-host disease 4B24 Approved [14]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [15]
Ivermectin DMDBX5F Intestinal strongyloidiasis due to nematode parasite 1F6B Approved [16]
Rosiglitazone DMILWZR Chronic kidney disease GB61 Approved [17]
Cupric Sulfate DMP0NFQ Fungal infection 1F29-1F2F Approved [18]
Cisplatin DMRHGI9 Adenocarcinoma 2D40 Approved [19]
Benzo(a)pyrene DMN7J43 N. A. N. A. Phase 1 [20]
PMID28460551-Compound-2 DM4DOUB N. A. N. A. Patented [21]
PMID28870136-Compound-52 DMFDERP N. A. N. A. Patented [22]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Fibroblast growth factor receptor 1 (FGFR1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [23]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [24]
Isotretinoin DM4QTBN Acne vulgaris ED80 Approved [25]
Chlorpromazine DMBGZI3 Acute intermittent hepatic porphyria 5C58.11 Approved [26]
Arsenic trioxide DM61TA4 Acute lymphoblastic leukaemia 2A85 Approved [27]
Lenalidomide DM6Q7U4 Adult T-cell leukemia/lymphoma Approved [28]
Thalidomide DM70BU5 Adult T-cell leukemia/lymphoma Approved [28]
Calcitriol DM8ZVJ7 Congenital alopecia LC30 Approved [29]
Ciclosporin DMAZJFX Graft-versus-host disease 4B24 Approved [14]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [15]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Substance-P receptor (TACR1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [30]
Bardoxolone methyl DMODA2X Mixed connective tissue disease 4A43.3 Phase 3 [31]
Benzo(a)pyrene DMN7J43 N. A. N. A. Phase 1 [32]
bisphenol A DM2ZLD7 Discovery agent N.A. Investigative [33]
Manganese DMKT129 N. A. N. A. Investigative [34]
taurine DMVW7N3 Discovery agent N.A. Investigative [35]
⏷ Show the Full List of 6 Drug(s)
Drug(s) Affected By Mitogen-activated protein kinase 3 (MAPK3)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Cisplatin DMRHGI9 Adenocarcinoma 2D40 Approved [36]
Progesterone DMUY35B Amenorrhea GA20.0 Approved [37]
Cannabidiol DM0659E Dravet syndrome 8A61.11 Approved [38]
Sertraline DM0FB1J Coronary heart disease BA80.Z Approved [39]
Beta-carotene DM0RXBT Vitamin deficiency 5B55-5B71 Approved [40]
Fulvestrant DM0YZC6 Breast cancer 2C60-2C65 Approved [41]
Secobarbital DM14RF5 Epilepsy 8A60-8A68 Approved [42]
Gefitinib DM15F0X Colon adenocarcinoma Approved [43]
Fexofenadine DM17ONX Allergic rhinitis CA08.0 Approved [44]
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [45]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Mitogen-activated protein kinase 1 (MAPK1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Ethanol DMDRQZU Chronic pain MG30 Approved [46]
Progesterone DMUY35B Amenorrhea GA20.0 Approved [37]
Carvedilol DMHTEAO Chronic heart failure BD1Z Approved [47]
Paclitaxel DMLB81S Breast carcinoma Approved [48]
Etoposide DMNH3PG Acute myelogenous leukaemia 2A41 Approved [49]
Cisplatin DMRHGI9 Adenocarcinoma 2D40 Approved [36]
Urokinase DM0GOUD Myocardial infarction BA41-BA43 Approved [50]
Cannabidiol DM0659E Dravet syndrome 8A61.11 Approved [51]
Sertraline DM0FB1J Coronary heart disease BA80.Z Approved [39]
Beta-carotene DM0RXBT Vitamin deficiency 5B55-5B71 Approved [40]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Signal transducer and activator of transcription 3 (STAT3)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Dexamethasone DMMWZET Acute adrenal insufficiency Approved [50]
Cannabidiol DM0659E Dravet syndrome 8A61.11 Approved [51]
Sertraline DM0FB1J Coronary heart disease BA80.Z Approved [52]
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [53]
Trametinib DM2JGQ3 Melanoma 2C30 Approved [54]
Sulindac DM2QHZU Acute myelogenous leukaemia 2A41 Approved [55]
Methotrexate DM2TEOL Anterior urethra cancer Approved [56]
Simvastatin DM30SGU Arteriosclerosis BD40 Approved [57]
Cladribine DM3JDRP Hairy cell leukaemia 2A82.2 Approved [58]
Quercetin DM3NC4M Obesity 5B81 Approved [59]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Fibroblast growth factor receptor 3 (FGFR3) TTST7KB FGFR3_HUMAN Inhibitor [1]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
Centrosomal protein 43 (CEP43) OT8TRHCF CEP43_HUMAN Gene/Protein Processing [2]
Fibroblast growth factor receptor 1 (FGFR1) OT4GLCXW FGFR1_HUMAN Gene/Protein Processing [3]
Mitogen-activated protein kinase 1 (MAPK1) OTH85PI5 MK01_HUMAN Gene/Protein Processing [4]
Mitogen-activated protein kinase 3 (MAPK3) OTCYKGKO MK03_HUMAN Gene/Protein Processing [4]
Signal transducer and activator of transcription 3 (STAT3) OTAAGKYZ STAT3_HUMAN Gene/Protein Processing [4]
Substance-P receptor (TACR1) OTCL9OC5 NK1R_HUMAN Gene/Protein Processing [5]

References

1 Emerging therapies for multiple myeloma. Expert Opin Emerg Drugs. 2009 Mar;14(1):99-127.
2 Oncogenic tyrosine kinase of malignant hemopathy targets the centrosome. Cancer Res. 2005 Aug 15;65(16):7231-40. doi: 10.1158/0008-5472.CAN-04-4167.
3 FGFR3 as a therapeutic target of the small molecule inhibitor PKC412 in hematopoietic malignancies. Oncogene. 2005 Dec 15;24(56):8259-67. doi: 10.1038/sj.onc.1208989.
4 Preclinical studies of fibroblast growth factor receptor 3 as a therapeutic target in multiple myeloma. Br J Haematol. 2004 Mar;124(5):595-603. doi: 10.1111/j.1365-2141.2004.04814.x.
5 Regulation of neurokinin-1 receptor messenger RNA expression in synovial fibroblasts of patients with rheumatoid arthritis. Neuropeptides. 2005 Oct;39(5):467-74. doi: 10.1016/j.npep.2005.07.005. Epub 2005 Sep 9.
6 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
7 E-3810 is a potent dual inhibitor of VEGFR and FGFR that exerts antitumor activity in multiple preclinical models. Cancer Res. 2011 Feb 15;71(4):1396-405.
8 A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
9 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
10 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
11 In vitro and in vivo characterization of Recifercept, a soluble fibroblast growth factor receptor 3, as treatment for achondroplasia. PLoS One. 2020 Dec 28;15(12):e0244368.
12 MK-2461, a novel multitargeted kinase inhibitor, preferentially inhibits the activated c-Met receptor. Cancer Res. 2010 Feb 15;70(4):1524-33.
13 Global gene expression analysis reveals differences in cellular responses to hydroxyl- and superoxide anion radical-induced oxidative stress in caco-2 cells. Toxicol Sci. 2010 Apr;114(2):193-203. doi: 10.1093/toxsci/kfp309. Epub 2009 Dec 31.
14 Integrating multiple omics to unravel mechanisms of Cyclosporin A induced hepatotoxicity in vitro. Toxicol In Vitro. 2015 Apr;29(3):489-501.
15 Integrative omics data analyses of repeated dose toxicity of valproic acid in vitro reveal new mechanisms of steatosis induction. Toxicology. 2018 Jan 15;393:160-170.
16 Quantitative proteomics reveals a broad-spectrum antiviral property of ivermectin, benefiting for COVID-19 treatment. J Cell Physiol. 2021 Apr;236(4):2959-2975. doi: 10.1002/jcp.30055. Epub 2020 Sep 22.
17 Rosiglitazone sensitizes MDA-MB-231 breast cancer cells to anti-tumour effects of tumour necrosis factor-alpha, CH11 and CYC202. Endocr Relat Cancer. 2007 Jun;14(2):305-15. doi: 10.1677/ERC-06-0003.
18 Physiological and toxicological transcriptome changes in HepG2 cells exposed to copper. Physiol Genomics. 2009 Aug 7;38(3):386-401.
19 Activation of AIFM2 enhances apoptosis of human lung cancer cells undergoing toxicological stress. Toxicol Lett. 2016 Sep 6;258:227-236.
20 New insights into BaP-induced toxicity: role of major metabolites in transcriptomics and contribution to hepatocarcinogenesis. Arch Toxicol. 2016 Jun;90(6):1449-58.
21 Cell-based two-dimensional morphological assessment system to predict cancer drug-induced cardiotoxicity using human induced pluripotent stem cell-derived cardiomyocytes. Toxicol Appl Pharmacol. 2019 Nov 15;383:114761. doi: 10.1016/j.taap.2019.114761. Epub 2019 Sep 15.
22 Quantitative phosphoproteomics reveal cellular responses from caffeine, coumarin and quercetin in treated HepG2 cells. Toxicol Appl Pharmacol. 2022 Aug 15;449:116110. doi: 10.1016/j.taap.2022.116110. Epub 2022 Jun 7.
23 Microarray analysis of H2O2-, HNE-, or tBH-treated ARPE-19 cells. Free Radic Biol Med. 2002 Nov 15;33(10):1419-32.
24 Differential modulation of PI3-kinase/Akt pathway during all-trans retinoic acid- and Am80-induced HL-60 cell differentiation revealed by DNA microarray analysis. Biochem Pharmacol. 2004 Dec 1;68(11):2177-86.
25 Temporal changes in gene expression in the skin of patients treated with isotretinoin provide insight into its mechanism of action. Dermatoendocrinol. 2009 May;1(3):177-87.
26 Effects of chlorpromazine with and without UV irradiation on gene expression of HepG2 cells. Mutat Res. 2005 Aug 4;575(1-2):47-60. doi: 10.1016/j.mrfmmm.2005.03.002. Epub 2005 Apr 26.
27 Arsenic suppresses gene expression in promyelocytic leukemia cells partly through Sp1 oxidation. Blood. 2005 Jul 1;106(1):304-10.
28 Thalidomide and Its Analogs Differentially Target Fibroblast Growth Factor Receptors: Thalidomide Suppresses FGFR Gene Expression while Pomalidomide Dampens FGFR2 Activity. Chem Res Toxicol. 2019 Apr 15;32(4):589-602. doi: 10.1021/acs.chemrestox.8b00286. Epub 2019 Mar 15.
29 Identification of vitamin D3 target genes in human breast cancer tissue. J Steroid Biochem Mol Biol. 2016 Nov;164:90-97.
30 Valproic acid inhibits substance P-induced activation of protein kinase C epsilon and expression of the substance P receptor. J Neurochem. 2003 Jul;86(1):69-76. doi: 10.1046/j.1471-4159.2003.01802.x.
31 Characterization of the potent, selective Nrf2 activator, 3-(pyridin-3-ylsulfonyl)-5-(trifluoromethyl)-2H-chromen-2-one, in cellular and in vivo models of pulmonary oxidative stress. J Pharmacol Exp Ther. 2017 Oct;363(1):114-125.
32 Air pollution and DNA methylation alterations in lung cancer: A systematic and comparative study. Oncotarget. 2017 Jan 3;8(1):1369-1391. doi: 10.18632/oncotarget.13622.
33 DNA methylome-wide alterations associated with estrogen receptor-dependent effects of bisphenols in breast cancer. Clin Epigenetics. 2019 Oct 10;11(1):138. doi: 10.1186/s13148-019-0725-y.
34 Gene expression profiling of human primary astrocytes exposed to manganese chloride indicates selective effects on several functions of the cells. Neurotoxicology. 2007 May;28(3):478-89.
35 Taurine-responsive genes related to signal transduction as identified by cDNA microarray analyses of HepG2 cells. J Med Food. 2006 Spring;9(1):33-41. doi: 10.1089/jmf.2006.9.33.
36 Treatment with anticancer agents induces dysregulation of specific Wnt signaling pathways in human ovarian luteinized granulosa cells in vitro. Toxicol Sci. 2013 Nov;136(1):183-92. doi: 10.1093/toxsci/kft175. Epub 2013 Aug 16.
37 Progesterone increases csk homologous kinase in HMC-1560 human mast cells and reduces cell proliferation. J Cell Biochem. 2007 Dec 1;102(5):1271-80. doi: 10.1002/jcb.21357.
38 Cannabidiol upregulates melanogenesis through CB1 dependent pathway by activating p38 MAPK and p42/44 MAPK. Chem Biol Interact. 2017 Aug 1;273:107-114. doi: 10.1016/j.cbi.2017.06.005. Epub 2017 Jun 7.
39 Sertraline, an antidepressant, induces apoptosis in hepatic cells through the mitogen-activated protein kinase pathway. Toxicol Sci. 2014 Feb;137(2):404-15. doi: 10.1093/toxsci/kft254. Epub 2013 Nov 5.
40 Growth stimulation of human pulmonary adenocarcinoma cells and small airway epithelial cells by beta-carotene via activation of cAMP, PKA, CREB and ERK1/2. Int J Cancer. 2006 Mar 15;118(6):1370-80. doi: 10.1002/ijc.21537.
41 Estrogen and pure antiestrogen fulvestrant (ICI 182 780) augment cell-matrigel adhesion of MCF-7 breast cancer cells through a novel G protein coupled estrogen receptor (GPR30)-to-calpain signaling axis. Toxicol Appl Pharmacol. 2014 Mar 1;275(2):176-81. doi: 10.1016/j.taap.2014.01.005. Epub 2014 Jan 17.
42 Inhibition of activator protein 1 by barbiturates is mediated by differential effects on mitogen-activated protein kinases and the small G proteins ras and rac-1. J Pharmacol Exp Ther. 2004 Dec;311(3):1232-40. doi: 10.1124/jpet.104.071332. Epub 2004 Jul 19.
43 Growth of hormone-dependent MCF-7 breast cancer cells is promoted by constitutive caveolin-1 whose expression is lost in an EGF-R-mediated manner during development of tamoxifen resistance. Breast Cancer Res Treat. 2010 Feb;119(3):575-91. doi: 10.1007/s10549-009-0355-8. Epub 2009 Mar 15.
44 Effect of histamine H1 receptor antagonists on TARC/CCL17 and MDC/CCL22 production from CD14+ cells induced by antigenic stimulation in vitro. Int Arch Allergy Immunol. 2011;155(1):38-51. doi: 10.1159/000318720. Epub 2010 Nov 25.
45 SIRT3 Mediates the Antioxidant Effect of Hydrogen Sulfide in Endothelial Cells. Antioxid Redox Signal. 2016 Feb 20;24(6):329-43. doi: 10.1089/ars.2015.6331. Epub 2015 Nov 10.
46 Downregulation of mitogen-activated protein kinases (MAPKs) in chronic ethanol-induced fatty liver. Toxicol Mech Methods. 2020 Jul;30(6):407-416. doi: 10.1080/15376516.2020.1747126. Epub 2020 Apr 1.
47 A unique mechanism of beta-blocker action: carvedilol stimulates beta-arrestin signaling. Proc Natl Acad Sci U S A. 2007 Oct 16;104(42):16657-62. doi: 10.1073/pnas.0707936104. Epub 2007 Oct 9.
48 The stent-eluting drugs sirolimus and paclitaxel suppress healing of the endothelium by induction of autophagy. Am J Pathol. 2009 Nov;175(5):2226-34.
49 Modulation of apoptosis in HaCaT keratinocytes via differential regulation of ERK signaling pathway by flavonoids. J Biol Chem. 2005 Sep 9;280(36):31498-507. doi: 10.1074/jbc.M505537200. Epub 2005 Jul 13.
50 ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
51 Cannabidiol Modulates the Immunophenotype and Inhibits the Activation of the Inflammasome in Human Gingival Mesenchymal Stem Cells. Front Physiol. 2016 Nov 24;7:559. doi: 10.3389/fphys.2016.00559. eCollection 2016.
52 Immunomodulatory effect of selective serotonin reuptake inhibitors (SSRIs) on human T lymphocyte function and gene expression. Eur Neuropsychopharmacol. 2007 Dec;17(12):774-80.
53 Diesel exhaust particulate-induced activation of Stat3 requires activities of EGFR and Src in airway epithelial cells. Am J Physiol Lung Cell Mol Physiol. 2007 Feb;292(2):L422-9. doi: 10.1152/ajplung.00204.2006. Epub 2006 Oct 6.
54 Physapubescin B enhances the sensitivity of gastric cancer cells to trametinib by inhibiting the STAT3 signaling pathway. Toxicol Appl Pharmacol. 2020 Dec 1;408:115273. doi: 10.1016/j.taap.2020.115273. Epub 2020 Oct 6.
55 Sulindac induces apoptosis and inhibits tumor growth in vivo in head and neck squamous cell carcinoma. Neoplasia. 2007 Mar;9(3):192-9. doi: 10.1593/neo.06781.
56 Global molecular effects of tocilizumab therapy in rheumatoid arthritis synovium. Arthritis Rheumatol. 2014 Jan;66(1):15-23.
57 Simvastatin acts as an inhibitor of interferon gamma-induced cycloxygenase-2 expression in human THP-1 cells, but not in murine RAW264.7 cells. Biocell. 2009 Aug;33(2):107-14.
58 Therapeutic potential of cladribine in combination with STAT3 inhibitor against multiple myeloma. BMC Cancer. 2011 Jun 16;11:255. doi: 10.1186/1471-2407-11-255.
59 Quercetin exerts anti-melanoma activities and inhibits STAT3 signaling. Biochem Pharmacol. 2014 Feb 1;87(3):424-34. doi: 10.1016/j.bcp.2013.11.008. Epub 2013 Nov 23.